# Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota

> **NCT03863730** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Odense University Hospital** · enrollment: 56 (actual)

## Conditions studied

- Alcoholic Liver Disease
- Liver Cirrhosis, Alcoholic
- Probiotics
- Liver Fibrosis

## Interventions

- **DIETARY_SUPPLEMENT:** Profermin Plus, FSMP, probiotics
- **DIETARY_SUPPLEMENT:** Fresubin, dietary supplement

## Key facts

- **NCT ID:** NCT03863730
- **Lead sponsor:** Odense University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-01
- **Primary completion:** 2021-07-15
- **Final completion:** 2031-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03863730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03863730, "Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT03863730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*